Oryzon Genomics has announced changes on its corporate governing bodies. The company has incorporated to its Board of Directors Dr. José Carlos Gutiérrez-Ramos, president and CEO of Synlogic Inc. (SYBX, NASDAQ) as independent director. Dr. Gutiérrez-Ramos is a key addition for the company in its expansion plans in the US market. 

Between 2009-2015, he was group senior vicepresident at Pfizer and head of its research center in Cambridge/Boston. In his current role as founder and CEO of Synlogic he has raised more than 200 million dollars with the participation of specialized investment funds.

In the same meeting of the Board the resignation of the directors representing Najeti has been tendered. It is a private investment fund founded in France in 1994. Najeti currently owns 20.54% of Oryzon's capital. After this revamp, Oryzon’s Board of Directors is composed of seven directors, of which four are independent Directors.

Oryzon has also reported financial results and corporate update of 2017. 

Photo: José Carlos Gutiérrez-Ramos, new independent director - Oryzon/Bolsamanía